SEARCH

Standard Essential Patents (SEPs) & FRAND Licencing

Angel IP. Standard Essential Patents (SEPs) & FRAND Licencing

Standard Essential Patents

A standard essential patent (SEP) is a patent which can be properly mapped onto a mandatory industry standard, such that a product which conforms to that standard infringes the patent. SEPs are common in the mobile telephony and telecommunications industry, a sector which is highly standardised due mainly to the need for interoperability between mobile devices.

SEPs, if truly “essential” to the standard, are difficult to avoid and are particularly powerful patents. For this reason, they are subject to the special licensing rules, FRAND rules (see separate section), but are nevertheless the subject of many patent disputes, the so-called “patent wars”. SEPs may be registered (“declared”) by their owners at ETSI (European Telecommunications Standard Institute) or other institutions, as appropriate.

Angel IP has extensive experience in SEPs and IP in the telecommunications sector, and has advised both SEP owners and manufacturers (SEP licensees).

FRAND licensing

If a patent is declared essential to a standard (ie as an SEP) the owner agrees that the patent be subject to the FRAND declaration, ie that licenses to the SEP will be granted on a Fair, Reasonable And Non-Discriminatory basis. Generally speaking license offers are to a portfolio of SEPs and state a license fee for use of the patents in the portfolio.

There is no definition per se of FRAND or what is fair, reasonable and non-discriminatory, sometimes leading to disagreements between owners and potential licensees about whether license offers made by the patent owner are indeed FRAND. Differences frequently relate to whether the patents are indeed SEPs (ie whether they correctly map on to the relevant standard) or the computation of the license fees is disputed.

SEPs and FRAND are cross-jurisdictional issues and the case law originates in a variety of different jurisdictions including the CJEU, US federal courts, UK courts and German courts.

At Angel IP we have considerable experience in FRAND licensing matters, from both licensor and licensee perspectives, with cases before UK courts and in arbitration. We have led FRAND negotiations (written and oral) on behalf of clients and have developed a number of strategies and tools for the conduct of such negotiations.

INTELLECTUAL PROPERTY
RIGHTS & BREXIT

At time of drafting this note the final form of any exit by the UK from the EU is uncertain...
READ MORE

UNITARY PATENT AND UNIFIED PATENT COURT

In reforms representing the most radical changes to the patent system...
READ MORE

WHY BOTHER PROTECTING MY IP? IS IT WORTH THE EXPENSE?

Protecting your IP may be expensive and may itself represent a considerable investment...
READ MORE

INTERNATIONAL IP PROTECTION STRATEGIES

It is unusual for a new product or technical innovation to be marketable in a single national economy...
READ MORE

PATENTS AND TAX
ADVANTAGES

A number of countries, including the UK, have fiscal arrangements in place offering reduced tax rates...
READ MORE

Physics

The scope of our work encompasses all the physical sciences but with particular emphasis on the optics, interferometry, communications, navigation, sensor and measurement technology.

Engineering

We cover all the engineering disciplines with a particular focus on aerospace, mechanical power generation, automotive and new technologies.

Electronics

Over the years we have worked on hundreds of patents in the electronic and computing sectors, reflecting a vast number of technical applications.

Communications

Mobile telephony and cellular technologies, whether in patent prosecution or licensing or disputes is a particular strength of Angel IP. We have considerable experience in standard essential patents (SEPs) and FRAND licenses.

Environmental

We have garnered considerable expertise across green technologies – in solar and wind power, as well as energy conservation devices.

Medical and Life Sciences

In life sciences Angel IP works in medical devices, as well as biotech and pharmaceuticals.